298 related articles for article (PubMed ID: 21156282)
21. Overexpression of heme oxygenase-1 induced by constitutively activated NF-κB as a potential therapeutic target for activated B-cell-like diffuse large B-cell lymphoma.
Huang J; Guo P; Ma D; Lin X; Fang Q; Wang J
Int J Oncol; 2016 Jul; 49(1):253-64. PubMed ID: 27211510
[TBL] [Abstract][Full Text] [Related]
22. An oncogenic role for alternative NF-κB signaling in DLBCL revealed upon deregulated BCL6 expression.
Zhang B; Calado DP; Wang Z; Fröhler S; Köchert K; Qian Y; Koralov SB; Schmidt-Supprian M; Sasaki Y; Unitt C; Rodig S; Chen W; Dalla-Favera R; Alt FW; Pasqualucci L; Rajewsky K
Cell Rep; 2015 May; 11(5):715-26. PubMed ID: 25921526
[TBL] [Abstract][Full Text] [Related]
23. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.
Pham LV; Fu L; Tamayo AT; Bueso-Ramos C; Drakos E; Vega F; Medeiros LJ; Ford RJ
Blood; 2011 Jan; 117(1):200-10. PubMed ID: 20889926
[TBL] [Abstract][Full Text] [Related]
24. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
Dunleavy K; Pittaluga S; Czuczman MS; Dave SS; Wright G; Grant N; Shovlin M; Jaffe ES; Janik JE; Staudt LM; Wilson WH
Blood; 2009 Jun; 113(24):6069-76. PubMed ID: 19380866
[TBL] [Abstract][Full Text] [Related]
25. Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen.
Lam LT; Davis RE; Ngo VN; Lenz G; Wright G; Xu W; Zhao H; Yu X; Dang L; Staudt LM
Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20798-803. PubMed ID: 19104039
[TBL] [Abstract][Full Text] [Related]
26. Targeting BCL10 by small peptides for the treatment of B cell lymphoma.
Bao W; Sun C; Sun X; He M; Yu H; Yan W; Wen F; Zhang L; Yang C
Theranostics; 2020; 10(25):11622-11636. PubMed ID: 33052237
[No Abstract] [Full Text] [Related]
27. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.
Zhang M; Xu-Monette ZY; Li L; Manyam GC; Visco C; Tzankov A; Wang J; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Pham LV; Young KH
Aging (Albany NY); 2016 Dec; 8(12):3321-3340. PubMed ID: 27941215
[TBL] [Abstract][Full Text] [Related]
28. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.
Lu X; Nechushtan H; Ding F; Rosado MF; Singal R; Alizadeh AA; Lossos IS
Blood; 2005 Apr; 105(7):2924-32. PubMed ID: 15591113
[TBL] [Abstract][Full Text] [Related]
29. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Lenz G; Wright GW; Emre NC; Kohlhammer H; Dave SS; Davis RE; Carty S; Lam LT; Shaffer AL; Xiao W; Powell J; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Campo E; Jaffe ES; Delabie J; Smeland EB; Rimsza LM; Fisher RI; Weisenburger DD; Chan WC; Staudt LM
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13520-5. PubMed ID: 18765795
[TBL] [Abstract][Full Text] [Related]
30. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.
Kloo B; Nagel D; Pfeifer M; Grau M; Düwel M; Vincendeau M; Dörken B; Lenz P; Lenz G; Krappmann D
Proc Natl Acad Sci U S A; 2011 Jan; 108(1):272-7. PubMed ID: 21173233
[TBL] [Abstract][Full Text] [Related]
31. The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.
Eluard B; Nuan-Aliman S; Faumont N; Collares D; Bordereaux D; Montagne A; Martins I; Cagnard N; Caly M; Taoui O; Lordello L; Lehmann-Che J; Tesson B; Martinez-Climent JA; Copie-Bergman C; Haioun C; Tilly H; Bonsang B; Vincent-Salomon A; Jais JP; Jardin F; Leroy K; Maiuri MC; Kroemer G; Molina TJ; Feuillard J; Baud V
Blood; 2022 Jan; 139(3):384-398. PubMed ID: 34232979
[TBL] [Abstract][Full Text] [Related]
32. LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells.
Jo T; Nishikori M; Kogure Y; Arima H; Sasaki K; Sasaki Y; Nakagawa T; Iwai F; Momose S; Shiraishi A; Kiyonari H; Kagaya N; Onuki T; Shin-Ya K; Yoshida M; Kataoka K; Ogawa S; Iwai K; Takaori-Kondo A
Blood; 2020 Aug; 136(6):684-697. PubMed ID: 32325488
[TBL] [Abstract][Full Text] [Related]
33. [PROGNOSTIC ROLE OF NF-κB EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA SUBGROUPS].
Škunca Z; Planinc-Peraica A
Acta Med Croatica; 2015 Mar; 69(1):25-32. PubMed ID: 26606782
[TBL] [Abstract][Full Text] [Related]
34. Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL.
Schmitt A; Xu W; Bucher P; Grimm M; Konantz M; Horn H; Zapukhlyak M; Berning P; Brändle M; Jarboui MA; Schönfeld C; Boldt K; Rosenwald A; Ott G; Grau M; Klener P; Vockova P; Lengerke C; Lenz G; Schulze-Osthoff K; Hailfinger S
Blood; 2021 Sep; 138(10):871-884. PubMed ID: 33876201
[TBL] [Abstract][Full Text] [Related]
35. Generation and Surgical Analysis of Genetic Mouse Models to Study NF-κB-Driven Pathogenesis of Diffuse Large B Cell Lymphoma.
Maybury BD; Saavedra-Torres Y; Snoeks TJA; Fitzgibbon J; Calado DP
Methods Mol Biol; 2021; 2366():321-342. PubMed ID: 34236648
[TBL] [Abstract][Full Text] [Related]
36. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.
Boudesco C; Verhoeyen E; Martin L; Chassagne-Clement C; Salmi L; Mhaidly R; Pangault C; Fest T; Ramla S; Jardin F; Wolz OO; Weber ANR; Garrido C; Jego G
Blood; 2018 Aug; 132(5):510-520. PubMed ID: 29871863
[TBL] [Abstract][Full Text] [Related]
37. Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma.
Liu YY; Leboeuf C; Shi JY; Li JM; Wang L; Shen Y; Garcia JF; Shen ZX; Chen Z; Janin A; Chen SJ; Zhao WL
Blood; 2007 Jul; 110(1):339-44. PubMed ID: 17379744
[TBL] [Abstract][Full Text] [Related]
38. Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival.
Bidère N; Ngo VN; Lee J; Collins C; Zheng L; Wan F; Davis RE; Lenz G; Anderson DE; Arnoult D; Vazquez A; Sakai K; Zhang J; Meng Z; Veenstra TD; Staudt LM; Lenardo MJ
Nature; 2009 Mar; 458(7234):92-6. PubMed ID: 19118383
[TBL] [Abstract][Full Text] [Related]
39. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.
Ding BB; Yu JJ; Yu RY; Mendez LM; Shaknovich R; Zhang Y; Cattoretti G; Ye BH
Blood; 2008 Feb; 111(3):1515-23. PubMed ID: 17951530
[TBL] [Abstract][Full Text] [Related]
40. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]